São Paulo - Delayed Quote BRL

GSK plc (G1SK34.SA)

Compare
41.53
+0.01
+(0.02%)
As of 3:55:23 PM GMT-3. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in BRL.
NameTitlePayExercisedYear Born
Ms. Emma Natasha Walmsley CEO & Director 38.87M 388.85M 1969
Ms. Julie Belita Brown A.C.A. CFO & Executive Director 37.1M -- 1962
Ms. Shobie Ramakrishnan Chief Digital & Technology Officer -- -- 1971
Mr. Tony Wood Chief Scientific Officer and Head of R&D -- -- --
Mr. Nick Stone SVP & Head of Investor Relations -- -- --
Mr. James Ford Senior VP & Group General Counsel of Legal & Compliance -- -- --
Ms. Sally Jackson Senior Vice President of Global Communications & CEO Office -- -- --
Mr. David Simon Redfern BSc (Hons), CA President of Corporate Development -- -- 1966
Ms. Diana Conrad Chief People Officer -- -- --
Mr. Philip C. Thomson President of Global Affairs -- -- --

GSK plc

980 Great West Road
Middlesex
Brentford, TW8 9GS
United Kingdom
44 20 8047 5000 https://www.gsk.com
Sector: 
Healthcare

Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Corporate Governance

GSK plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 20, 2025 at 12:00 AM UTC

Ex-Dividend Date

April 30, 2025 at 7:30 AM UTC

GSK plc Earnings Date

Recent Events

Waiting for permission
Allow microphone access to enable voice search

Try again.